Durolane Injection

Introduction to DUROLANE

Durolane Injection

References

  1. Leighton R, Åkermark C, Therrien R, et NASHA hyaluronic acid vs. methylprednisolone for knee osteoarthritis: a prospective, multi-centre, randomized, non-inferiority trial. Osteoarthritis Cartilage. 2014;221:17–25.
  2. Bioventus MA-12200 Study report, open-label extension study 3, DUROLANE vs MPA. Data on file, RPT-00641.
  3. McGrath AF, McGrath AM, Jessop ZM, et al. A comparison of intra-articular hyaluronic acid competitors in the treatment of mild to moderate knee J Arthritis. 2013;21:108. doi: 10.4172/2167-7921.1000108.
  4. Ågerup B, Berg P, Åkermark Non-animal stabilized hyaluronic acid: a new formulation for the treatment of osteoarthritis. BioDrugs. 2005;19(1):23-30.
  5. Edsman K, Hjelm R, Lärkner H, et Intra-articular duration of Durolane™ after single injection into the rabbit knee. Cartilage. 2011;2(4):384-8.
  6. Lindqvist U, Tolmachev V, Kairemo K, Aström G, Jonsson E, Lundqvist Elimination of stabilised hyaluronan from the knee joint in healthy men. Clin Pharmacokinet. 2002;41(8):603-13.
  7. Larsen NE, Dursema HD, Pollak CT, Skrabut Clearance kinetics of a hylan-based viscosupplement after intra-articular and intravenous administration in animal models. J Biomed Mater Res B Appl Biomater. 2012;1002:457–62.
  8. Brown TJ, Laurent UB, Fraser Turnover of hyaluronan in synovial joints: elimination of labelled hyaluronan from the knee joint of the rabbit. Exp Physiol. 1991;761:125–34.